Reports Q1 revenue $16.146M, consensus $4.12M. “Based on encouraging early responses with late-stage patients across multiple tumor types, we are actively studying dose ranges from 5.4 mg/kg to 8 mg/kg, refining our understanding of PYX-201’s therapeutic window. We are on track to report the comprehensive dataset in the fall of 2024, and we look forward to the potential future robust development plan supported by our strong balance sheet,” said Lara Sullivan, M.D., President and CEO of Pyxis Oncology.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYXS:
- Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
- Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
- PYXS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Pyxis Oncology assumed with a Buy at Jefferies
- Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)